| Lexaria Bioscience Corp. (LEXX) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | |
| Balance Sheet Date | 2025-Nov-30 | 2024-Nov-30 | 2023-Nov-30 | 2022-Nov-30 | 2021-Nov-30 | 2020-Nov-30 | 2019-Nov-30 | 2018-Nov-30 | 2017-Nov-30 | 2016-Nov-30 | 2015-Nov-30 | 2015-Aug-31 | 2015-Feb-28 | 2014-Nov-30 | 2014-Jul-31 | 2014-Apr-30 | |||||||||||||||||||||||||||||||||
| Fiscal Period | Q4-FY2025 | Q4-FY2024 | Q4-FY2023 | Q4-FY2022 | Q4-FY2021 | Q4-FY2020 | Q4-FY2019 | Q4-FY2018 | Q4-FY2017 | Q4-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q3-FY2014 | Q2-FY2014 | |||||||||||||||||||||||||||||||||
| Operating Cash Flow | (984,098$) | (2,726,045$) | (1,181,653$) | (1,245,313$) | (1,166,324$) | (809,533$) | (555,079$) | (564,314$) | (520,321$) | (100,987$) | (208,950$) | (360,862$) | (173,214$) | 453,681$ | (873,324$) | (220,202$) | |||||||||||||||||||||||||||||||||
| Investing Cash Flow | (5,099$) | (37,804$) | (40,026$) | (34,842$) | (58,215$) | (5,775$) | (5,710$) | (167,200$) | (85,715$) | (13,684$) | (3,094$) | 721,806$ | 0$ | (156,328$) | 12,508$ | 131,915$ | |||||||||||||||||||||||||||||||||
| Purchases of Property and Equipment | 24,645$ | 20,500$ | 42,375$ | 0$ | 0$ | 122,832$ | 0$ | 3,094$ | 0$ | 0$ | |||||||||||||||||||||||||||||||||||||||
| Financing Cash Flow | 3,474,051$ | 4,345,393$ | 1,819,370$ | (11,204$) | (10,987$) | (8,767$) | 706,704$ | 1,649,190$ | 282,402$ | 145,508$ | 36,000$ | 1$ | (98,743$) | (472,209$) | 1,701,800$ | 0$ | |||||||||||||||||||||||||||||||||
| End Cash Position | 4,300,000$ | 1,802,123$ | 4,600,000$ | 6,500,000$ | 8,078,254$ | 6,499,885$ | 8,459,081$ | 4,705,399$ | 1,954,165$ | 1,352,102$ | 3,163,906$ | 3,272,102$ | 4,533,063$ | 5,813,218$ | 7,051,083$ | 8,359,374$ | 9,682,271$ | 10,917,797$ | 8,108,512$ | 9,346,933$ | 525,341$ | 1,293,749$ | 2,034,011$ | 739,985$ | 1,333,321$ | 1,285,147$ | 1,995,842$ | 1,995,843$ | 2,644,860$ | 1,727,184$ | 2,063,369$ | 2,317,694$ | 2,209,703$ | 2,533,337$ | 2,788,978$ | 523,633$ | 124,246$ | 93,409$ | 37,102$ | 40,224$ | 84,031$ | 260,075$ | 792,018$ | 431,073$ | 703,030$ | 877,886$ | 36,902$ | ||
| Exchange Rate Effect | (5,744$) | (3,175$) | 4,372$ | ||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (984,098$) | (2,750,690$) | (1,181,653$) | (1,265,813$) | (1,208,699$) | (809,533$) | (555,079$) | (687,146$) | (520,321$) | (100,987$) | (212,044$) | (360,862$) | (173,214$) | 453,681$ | (873,324$) | (220,202$) | |||||||||||||||||||||||||||||||||